PDL BioPharma Profile

USD 0.03  1.18%

Exercise or conversion by Torres Laurie C of 2188 shares of PDL BioPharma subject to Rule 16b-3

PDL BioPharma insider trading alert for exercise of common stock by Torres Laurie C, VP Human Resources, on October 16, 2018. This event was filed by Pdl Biopharma Inc with SEC on 2005-12-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

PDL BioPharma Summary

PDL BioPharma is an interesting company.? They really do not make anything.? Instead, the finance patents within the pharma industry, providing financial monetization of royalty streams to companies and academic institutions.? Their market capitalization is $365 million and the stock is trading at $2.20 per share. ? Basically, what the company does is it finds patents that an institution or company has filed and then PDLI monetizes that patent.? Then, the company licenses the patent out taking in a spread between what the company pays to the patent holder and the fees collected by companies using the patent.? They are a middleman for the pharma patent industry. ? ? [more]
PDL BioPharma (PDLI) is traded on BATS Exchange in USA. It is located in Nevada U.S.A and employs 92 people. PDL BioPharma is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 344.6 M. PDL BioPharma conducts business under Healthcare sector and is part of Biotechnology industry. This company has 145.4 M outstanding shares of which 18.58 M shares are at this time shorted by private and institutional investors with about 16.7 trading days to cover. PDL BIOPHARMA INC currently holds about 395.65 M in cash with (12.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.72 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check PDL BioPharma Probability Of Bankruptcy

Ownership Allocation (%)

PDL BioPharma Target Price Odds Analysis

Odds Below 2.57HorizonTargetOdds Above 2.57
43.52%30 days 2.57 55.97%
Based on normal probability distribution, the odds of PDL BioPharma to move above current price in 30 days from now is about 55.97% (This PDL BioPharma probability density function shows the probability of PDL BioPharma Stock to fall within a particular range of prices over 30 days) .

PDL BioPharma Top Holders

PDL BioPharma Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Bank Of MontrealCommon Shares611 K1.6 M
Franklin Street Advisors IncCommon Shares20 K53 K
Linden Advisors LpDebt27.9 M25.7 M
View PDL BioPharma Diagnostics

PDL BioPharma Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

PDL BioPharma Key Fundamentals

PDL BioPharma Against Markets

PDL BioPharma Current Ratings

PDL BioPharma 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for PDL BioPharma are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 92 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
PDL BioPharma SEC Filings
PDL BioPharma SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NamePDL BioPharma
President CEO, DirectorJohn McLaughlinView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationNevada U.S.A
Business Address932 Southwood Boulevard
ExchangeBATS Exchange
CIK Number0000882104
Phone775 832 8500
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 31, 2018

PDL BioPharma Directors

PDL BioPharma Corporate Directors

David Gryska Independent Director
Samuel Saks Director
Harold Selick Independent Director
Additionally take a look at Your Equity Center. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.
Search macroaxis.com